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Ulcerative colitis (UC) is a dynamic, idiopathic, chronic inﬂam-
matory condition associated with a high colon cancer risk. Amer-
ican ginseng has antioxidant properties and targets many of the
players in inﬂammation. The aim of this study was to test whether
American ginseng extract prevents and treats colitis. Colitis in
mice was induced by the presence of 1% dextran sulfate sodium
(DSS) in the drinking water or by 1% oxazolone rectally. Amer-
ican ginseng extract was mixed in the chow at levels consistent
with that currently consumed by humans as a supplement (75
p.p.m., equivalent to 58 mg daily). To test prevention of colitis,
American ginseng extract was given prior to colitis induction. To
test treatment of colitis, American ginseng extract was given after
the onset of colitis. In vitro studies were performed to examine
mechanisms. Results indicate that American ginseng extract not
only prevents but it also treats colitis. Inducible nitric oxide syn-
thase and cyclooxygenase-2 (markers of inﬂammation) and p53
(induced by inﬂammatory stress) are also downregulated by
American ginseng. Mucosal and DNA damage associated with
colitis is at least in part a result of an oxidative burst from
overactive leukocytes. We therefore tested the hypothesis that
American ginseng extract can inhibit leukocyte activation and
subsequent epithelial cell DNAdamage invitro and invivo. Results
are consistent with this hypothesis. The use of American ginseng
extract represents a novel therapeutic approach for the preven-
tion and treatment of UC.
Introduction
Ulcerative colitis (UC) is a heterogenous, chronic and relapsing in-
ﬂammatory condition that has a signiﬁcant impact on the quality of
life. Millions of people have this disease and have an increased colon
cancer risk. Despite a wide variety of causes (e.g. environmental
factors, genetic susceptibility and imbalanced enteric bacteria), the
end result is an abnormal immune response with repeated episodes of
colonic inﬂammation. While not everyone with colitis will develop
colon cancer, risk increases when length of disease exceeds 10 years,
on the order of 0.5–1.0% per year (1). Conventional treatment of
colitis can reduce periods of active disease and help to maintain re-
mission, but these treatments often bring marginal results, patients
become refractory and there are side effects. For this reason, many
colitis sufferers turn to unconventional treatments in hopes of abating
symptoms of active disease and it is estimated that  40% of UC
patients use some form of megavitamin therapy of herbal/dietary
supplement (2,3).
The natural herbal American ginseng (Panax quinquefolius) im-
proves mental performance and detrimental end points associated
with diseases such as cardiovascular disease, diabetes and inﬂuenza
(4,5). These diseases are all associated with inﬂammation, and Amer-
ican ginseng is a putative antioxidant in that it targets many of the key
players involved in inﬂammation. Since UC is a chronic inﬂammatory
disease, we hypothesized that American ginseng can be used to treat
colitis. Here, we describe a role for American ginseng extract in the
prevention and treatment of colitis.
Materials and methods
Chemicals and reagents
American ginseng extract was purchased from the National Research Council
(NRC) of Canada, Institute for National Measurement Standards. The Amer-
ican ginseng roots were cultivated by Chai-Na-Ta Farms Ltd (Kamloops,
British Columbia, Canada), which is the largest producer of North American
ginseng in the world and alone accounts for 20% of global production. The
ginseng obtained by NRC and processed by Canadian Phytopharmaceuticals
Corporation (Richmond, British Columbia, Canada) was grown on the
Harper Ranch, Kamloops, British Columbia, Canada, and obtained from
the Harper 113 planting. The Harper 113 planting was made in 1999,
emerged as seedlings in 2000 and was harvested as 4-year olds in the fall
of 2003. Following grinding to pass 80 mesh, 35 kg of the root material was
extracted with aqueous ethanol (75% ethanol and 25% water) in a recirculat-
ing ﬁlter extraction system for 4 h at a temperature of 60C under vacuum.
The ratio of solvent to root was 8:1 (vol/wt). After extraction, the ﬁltrate was
partially dried invacuo to yield a concentrated extract; 2.8 kg of maltodextrin
(40% of ﬁnal weight) was then blended as a support and the resultant slurry
was spray dried to yield 7 kg of free ﬂowing powder. Analysis by Canadian
Phytopharmaceuticals Corporation by High-performance liquid chromatog-
raphy–ultraviolet against pure standards determined the total ginsenoside
content (as the sum of Rg1, Re, Rb1, Rc, Rb2 and Rd) of the ﬁnished material
to be 10.1% (wt/wt) and conﬁrmed by High-performance liquid chromatog-
raphy–mass spectrometry at the NRC of Canada. The ﬁnal powder form of
P.quinquefolius (American ginseng) extract supplied by Canadian Phytophar-
maceutical Corporation contains (wt/wt) 10.1% ginsenosides (Rg1, Re, Rb1,
Rc, Rb2 and Rd), 2% additional ginsenosides made up of F11, Ro, isomers of
Rd and traces of malonyl ginsenosides and 40% of maltodextrin derived from
hydrolyzed corn starch. The remaining 48% of the powder is made up of
ginseng root-derived polysaccharides/oligosaccharides and proteins and up
to 5% of moisture. The lot used was screened and found to be free of heavy
metals and contaminants.
Proximate analysis of American ginseng conducted at the University of
Guelph report a mean carbohydrate content of 73.4% and protein of 11.3%.
The majority of the polysaccharide component is reported by the Ontario
Ministry of Agriculture and Food to be starch. Using liquid chromatography-
mass spectrometry, the NRC Canada conducted independent evaluation of the
Abbreviations: COX-2, cyclooxygenase-2; DSS, dextran sulfate sodium; IFN,
interferon; iNOS, inducible nitric oxide synthase; NF-jB, nuclear factor-
kappa B; NRC, National Research Council; PBS, phosphate-buffered saline;
UC, ulcerative colitis.
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11.1% total ginsenosides (wt/wt); mass fractions (mg/g) for each of the ginse-
nosides were found as follows: Rg1 3.0, Re 23.7, Rb1 44.2, Rc 15.9 and Rd
23.5. The NRC Canada values were determined using external standards that
were obtained from Chromadex (Irvine, CA). Critically, liquid chromatogra-
phy-mass spectrometry conﬁrmed no detectable ginsenoside Rf characteristic
of Asian ginseng and the presence of ginsenoside F11.
It should be noted here, that regular AIN-93M chow fed to mice contains
12.5000% maltodextrin. The addition of 75 p.p.m. American ginseng in the
chow equates to 30 mg/kg ﬁnal concentration of maltodextrin added to
12.5000% already in the chow. Therefore, there is 12.5000% maltodextrin in
the AIN-93M chow and 12.5003% of maltodextrin in the AIN-93M chow
supplemented with 75 p.p.m. American ginseng extract.
Cell culture and treatment
Cell lines were maintained in Dulbecco’s modiﬁed Eagle’s media (Hyclone,
Logan, UT) supplemented with 10% fetal bovine serum (Bioﬂuids, Rockville,
MD), 4 mM glutamine (Bioﬂuids), penicillin (10 U/ml) and streptomycin
(10 lg/ml, Bioﬂuids). Experiments with American ginseng extract were car-
ried out by preincubating cells with 200 lg/ml American ginseng extract for
12 h. A total of 200 lg/ml was chosen on the basis of its ability to
inhibit inducible nitric oxide synthase (iNOS) levels by  50% (supplementary
Figure 1A is available at Carcinogenesis Online) and that this level is non-
toxic to the cell lines used here (supplementary Figure 1B and C is available
at Carcinogenesis Online). Cells were washed before exposure to 100 U/ml
interferon (IFN)-c (R&D Systems, Minneapolis, MN; ANA-1 cells alone)
or coculture of ANA-1 macrophagesand colon cancer cells describedas follows.
Coculture conditions
Coculture experiments were carried out as previously (6) with modiﬁcations.
HT29 colon cancer cells were seeded at 2.5   106 cells per 150 mm culture
dish 24 h before exposure to American ginseng (200 lg/ml) for 12 h. The
Americanginseng extract was washed off and then HT29 cells were exposed to
activated or non-activated ANA-1 murine macrophages. Log-phase ANA-1
murine macrophages were activated with IFN-c (100 U/ml; R&D Systems).
ANA-1 cells were thenadded to the actively growingcolon cancer cells at a 3:1
ratio (ANA-1:colon cancer cell). The coculture was incubated for time points
indicated in ﬁgures before harvest. After harvest, HT29 and ANA-1 cells were
separated with a MACS mini separator and CD45þ microbeads according to
the manufacturer’s instructions (Miltenyi BioTec, Auburn, CA). HT29 cells
were then examined for DNA damage by Comet analysis; ANA-1 cells were
examined for an oxidative burst by chemiluminescence.
Dextran sulfate sodium and oxazolone mouse models of colitis
An outline for all mouse models of colitis can be found in supplementary
Figure 2 (available at Carcinogenesis Online). For our dextran sulfate sodium
(DSS; MP Biomedicals, Solon, OH; 36 000–50 000 mw) mouse model, we
followed the method of Seril et al. (7). Brieﬂy, 8-week-old C57BL/6 mice
received either water ad libitum or 1% DSS. All mice were on an AIN76A
high iron diet. American ginseng extract was mixed into the chow of indicated
groups at 75 p.p.m. (Research Diets, New Brunswick, NJ), which is the human
equivalentdose of 58mgdaily.Thisis farbelowthatused inpreviousclinical
trials, where 1–3 g American ginseng has been shown to be effective in re-
ducing blood sugar levels in patients with diabetes and healthy people (8,9).
There are no signiﬁcant side effects with long-term consumption of 3 g Amer-
ican ginseng (10). Our calculation of the human equivalent amount of Amer-
ican ginseng consumed by mice uses the body surface area normalization
method (11) with the following assumptions: a typical mouse eats 3.5 g chow
daily and weighs 22 g; the average adult human weighs 60 kg. More specif-
ically, here, chow contains 75 p.p.m. Americanginseng extract. This equates to
75 mg/kg of chow. A mouse consumes 3.5 g chow daily. Therefore, 75 mg/
1000 g chow   3.5 g chow/day 5 0.2625 mg American ginseng extract daily.
If a mouse weighs on average 22 g, then 0.2625 mg/22 g   1000 g/1 kg 5
11.93 mg/kg daily. As discussed by Reagan-Shaw et al. (11), the human
equivalent dose (mg/kg) 5 animal dose (mg/kg)   (animal Km/human Km).
As such, human equivalent dose (mg/kg) for mouse 5 11.93 mg/kg/(3/
37) 5 0.967 mg/kg. If an average human adult weighs 60 kg, this equates to
0.967 mg/kg   60 kg 5 58 mg daily for humans. Mice consumed the same
amount of chow daily (on average 3.5 g) regardless of it containing American
ginseng extract (data not shown). We should note again here that the American
ginseng extract we use contains 40% maltodextrin and equates to 12.5003%
ﬁnal amount in chow supplemented with 75 p.p.m. American ginseng extract.
Chow without 75 p.p.m. American ginseng extract contains almost identical
amounts of maltodextrin (12.5000% ﬁnal conctration), making it unlikely any
differences in groups are due to this ingredient.
TodeterminewhetherAmerican ginsengextractprevents colitisonset,itwas
given to indicated groups of mice 1 week prior to and during DSS or water
treatment. Organs were harvested from the treated mice after either 2.5 cycles
(short-term treatment) or 14.5 cycles (long-term treatment), where each cycle
in the DSS groups consisted of 1% DSS in drinking water for 7 days, followed
by a 7 day interval (for short-termtreatment) or a 10 day interval (for long-term
treatment) with normal drinking water. To determine whether American gin-
seng extract can reverse/treat colitis, mice were fed DSS for 1.5 cycles (7 days
DSS, 7 days water and 7 days DSS) and then given regular chow or chow
containing American ginseng extract (75 p.p.m.). Micewere then euthanized at
1 cycle interval (another 7 days water and then 7 days DSS). For pathology and
immunohistochemistry, colon tissue samples were washed with phosphate-
buffered saline (PBS; Mediatech, Herndon, VA), cut longitudinally, swiss-
roled, then formalin ﬁxed and parafﬁn embedded. For western blot analysis,
colonic epithelial cells were obtained from scrapings of full-length colon
scrapings and immediately frozen at  80C.
For our oxazolone model, we followed the methods described by Wirtz
et al. (12). Brieﬂy, mice were fed normal chow or chow containing American
ginseng extract (75 p.p.m.) for 1 week prior to the initiation of the experi-
ment. On day 0, the skin of the mice was treated with either 150 llo f
oxazolone (Sigma, St Louis, MO) or 150 ll of vehicle control for presensi-
tization. The oxazolone presensitization solution is four parts acetone to one
part olive oil containing 3% (wt/vol) oxazolone. The vehicle control was four
parts acetone to one part olive oil alone. After 1 week, mice were weighed,
anesthetized and either 100 ll oxazolone solution or 100 ll vehicle control
was given by rectal administration. The oxazolone solution was 1% oxazo-
lone mixed into a 50% ethanol solution. The vehicle control was 50% ethanol
solution alone. Mice were held in a vertical position (head down) for 60 s and
then put back into their cages. After 4 days, mice were weighed, then eutha-
nized and colons were processed as above for pathology by swiss-roll, ﬁxa-
tion and parafﬁn embedding.
Immunohistochemical and immunoﬂuorescence staining
For immunohistochemical staining, serial sections of mouse colon tissues (pro-
cessed as described above) were incubated with antibodies against p53 (Mouse
monoclonal, clone Pab 122, cat# X1494; diluted 1 in 1 million, Exalpha Bio-
logicals, Maynard, MA), cyclooxygenase-2 (Cox-2) (Rabbit polyclonal, cat#
160126; diluted 1 in 20 000; Cayman Chemical, Ann Arbor, MI) or iNOS
(Mouse monoclonal, clone 5D5-H7, cat# MC-5245; diluted 1 in 10 000; Re-
search & Diagnostic Antibodies, North Las Vegas, NV). To ensure even stain-
ingandreproducibleresults,sectionswereincubated byslowrocking overnight
in primary antibodies (4C) using the Antibody AmpliﬁerTM (ProHisto, LLC,
Columbia, SC). Following incubation with primary antibody, sections were
processed with EnVisionþ System-HRP kits (DakoCytomation, Carpinteria,
CA) according to the kit protocols. The chromogen was diaminobenzidene and
sectionswerecounter stained with 1% methyl green.The positivecontrol tissue
was colon cancer sections. Immunohistochemistry was quantiﬁed using the
ACIS III Automated Cellular Imaging System (DakoCytomation). ACIS
III consists of an automated bright-ﬁeld microscopewith imageand proprietary
processing analysis software for evaluating tissue sections on glass microscope
slides. Results are represented as the percentage of cells staining positive.
For immunoﬂourescence, colons were harvested, ﬁxed in freshly prepared
4% paraformaldehyde in PBS buffer (pH 7.2) and thenvibratome sectioned at
100 lm. Tissue autoﬂuorescence was quenched by incubation of the sections
sequentially in PBS–glycine (150 mM) followed by NaBH4 (1 mg/ml in
PBS). CD4þ cells were labeled with Alexa Fluor 488-conjugated rat anti-
mouse CD4 monoclonal antibody (1:200, cat# 557667; Abcam, Cambridge,
MA). Nuclei of all cells were labeled with 4#,6-diamidino-2-phenylindole
(D3571, 1:5 000; Invitrogen, Carlsbad, CA). Finally, rhodamine phalloidin
(Invitrogen; cat# R415, green) was used to stain for F-actin (Molecular
Probes, Eugene, OR).
Generation of single-cell suspensions from mouse colons
In order to examine a leukocyte oxidative burst and associated epithelial cell
DNA damage in vivo, separation of appropriate cell types was required.
Accordingly, following treatment of mice for 2.5 cycles, we dissected out
the colon, ﬂushed it out with 1  PBS, opened it longitudinally and cut the
colon into two pieces. Colons were incubated in 10% fetal bovine serum/5 mM
ethylenediaminetetraacetic acid in 1  Ca2þ/Mg2þ-free PBS for 15 min at
room temperature. Colon tissues were then shaken to dislodge the epithelial
layer into single-cells suspensions. Cell viability was checked by trypan blue
exclusion and .95% cells were viable. The single-cell suspension was centri-
fuged (1500 r.p.m., 5 min), and the pellet was brought up in freezing media and
frozen at  80C until Comet analysis.
The remaining lamina propria was added to an enzyme cocktail consisting
of collagenase I (Sigma; 0.1 mg/ml) and dispase (EMD, Gibbstown, NJ; 0.2
mg/ml) for 75 min at 37C in a shaking water bath. The suspension was
further mechanically separated by pipetting and examined for trypan blue
exclusion. Again, .95% of the single-cell suspension was viable. The
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ads according to the manufacturer’s instructions (Miltenyi BioTec). Cells
were counted and equalized to the same number (1   106 cells), centrifuged
at 1500 r.p.m. for 5 min and then examined for an oxidative burst by chem-
iluminescence according to the manufacturer’s instructions (World Precision
Instruments, Sarasota, FL).
Quantifying inﬂammation
Slides were examined in a blind fashion by an experienced individual as de-
scribed previously (13). Brieﬂy, inﬂammation was graded by extent (focal,
multifocal, diffuse or extensive areas) and depth/penetration of inﬂammation
(lamina propria, into submucosa, into mucscularis propria and into subserosa).
Ulceration/erosion was assessed by the overall extent in the colonic tissue.
Both inﬂammation and ulceration/erosion were then given a numerical value
of 0–4, where 0 is none observed, and 4 is severe inﬂammation and/or ulcer-
ation/erosion. A score of 5 was given when there was fulminant colitis and
perforation leading to sepsis and death.
Western blot analysis and antibodies
Western blots were carried out as described previously (14). Antibodies used
include: iNOS (Rabbit polyclonal, diluted 1 in 1000; Caymen Chemicals, Ann
Arbor, MI), endothelial nitric oxide synthase (Rabbit polyclonal, diluted 1 in
500; BD Biosciences, San Jose, CA) and IkappaB-Phospho-Ser-32 (Rabbit
polyclonal, diluted 1 in 1000; Cell Signaling Technology., Danvers, MA).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary anti-
bodies were purchased from Amersham Biosciences (Piscataway, NJ). Both
secondary antibodies were diluted at 1:2000. All antibodies were diluted in 5%
milk/PBST (1% Tween 20 in 1  PBS). Western blot signal was detected by
Supersignal West Pico Chemiluminescent Substrate (Pierce Biotechnology,
Rockford, IL) and developed onto Hyperﬁlm (Amersham Biosciences).
Nitrate and nitrite assay
Nitrite and nitrate are the stable end products of NO metabolism and are mea-
sured in culture media with a ﬂuorometric assay kit as described by the vendor
(Caymen Chemicals). Brieﬂy, 10 ll of cell culture medium was incubated with
nitrate reductase and enzyme cofactor for 1 h. For mouse colon tissue, 10 ll
tissue homogenates were incubated for 2 h. Then, 2,3-diaminonaphthalene re-
agent was addedto each well. After 10min, NaOH was appliedto neutralize the
system. Results were read with FluoStar Galaxy (BMG, Durham, NC) ﬂuores-
cence spectrometer (kex 5 360 nm and kem 5 430 nm).
Measuring an oxidative burst
An oxidative burst from inﬂammatory cells was measured by two methods. We
ﬁrst measured chemiluminescence according to the kit directions (World Pre-
cision Instruments). Brieﬂy, collected inﬂammatory cells were washed and
resuspended at 1   106 cells in Hank’s buffered saline solution. Luminol
and enhancer solutions were added and then placed in a luminometer, which
quantiﬁes an oxidative burst through the reaction of luminal with reactive
oxygen species to produce a luminophore with an emission peak of 425 nm.
Luminescence intensity is proportional to the amount of reactive species
in the sample and is quantiﬁed as relative light units. We also examined re-
active oxygen species through an Amage-iTTM detection kit (Molecular
Probes), according to the kit directions. The technology is based on 5-(and
6)-carboxy-2#,7#-dichlorodihydroﬂuorescein diacetate, a reliable ﬂuorogenic
marker for reactive oxygen species in live cells.
Comet analysis
AnalkaliCometassaywasperformedaccordingtoinstructionsprovidedbythe
kit manufacturer (CometAssayTM, Trevigen, Gaithersburg, MD). Cells treated
with hydrogen peroxide (200 lM, 20 min.) were used as positive controls. A
minimum of 50 Comets per treatment were quantiﬁed after capturing with and
quantiﬁed by the Automated Comet Assay Analysis System (Loats Associates,
Westminster, MD). Olive tail moment (15) was used to evaluate DNA damage.
The tail moment, expressed in arbitrary units, is calculated by multiplying
the percent of DNA (ﬂuorescence) in the tail by the length of the tail in lm.
The tail length is measured between the edge of Comet head and the end of
the Comet tail. An advantage of using the tail moment as an index of DNA
damage is that both the amount of DNA damage and the distance of migration
of the genetic material in the tail are represented by a single number.
Statistical analysis
For prevention and treatment studies with inﬂammation and ulceration as an
end point, a contingency table analysis was done on the DSS and DSS þ
American ginseng groups to determine if there is a statistically signiﬁcant
differenceintheirinﬂammationandulcerationscores.Theuseofacontingency
table approach was motivated by the fact that the responses are categorical.
Because of small sample sizes and a multitude of cells with zero frequencies,
instead of computing the P-value using the chi-square distribution, we utilized
a generalized Fisher’s exact test approach. The use of the chi-square distribution in
such cases will not provide a reliable estimate of the P-values. The exact P-values
associated with the observed chi-square statistic values were computed using
a method developed by Mehta et al., which are implemented in the statistical
analysis system. For immunohistochemical quantiﬁcation, mean differences be-
tween groups were compared by one-way analysis of variance with Scheffe mul-
tiple comparison tests. The P-value chosen for signiﬁcance in this study was 0.05.
Results
American ginseng extract prevents DSS-induced colitis
There is an increasing evidence that American ginseng targets many
key players in inﬂammation (5). UC is a high colon cancer risk,
chronic inﬂammatory disease associated with overactive inﬂamma-
tory cells inﬁltrating the colon. We therefore tested the hypothesis that
American ginseng inhibits the onset of colitis. Table I shows results
that are consistent with this hypothesis. One percentage DSS stimu-
lates colitis. When American ginseng extract (75 p.p.m.) is given in
the diet 1 week prior to and during short-term (2.5 cycles) and long-
term (14.5 cycles) treatment with 1% DSS, mice are signiﬁcantly
protected from both inﬂammation (Table IA and B) and ulceration
(Table IC and D) associated with colitis. The exact P-value associated
with the observed chi-square value, under the hypothesis of no differ-
ences between the two groups (DSS versus DSS þ American gin-
seng), is 0.0006 for the inﬂammation score, short-term treatment
(Table IA); for the inﬂammation score the exact P-value was 0.0455,
long-term treatment (Table IB); for the ulceration score the exact
P-value was 0.0047, short-term treatment (Table IC) and for the ulcera-
tion score the exact P-value was 0.2030, long-term treatment (Table ID).
For the long-term experiment, we also observed that 14 mice died
of severe intestinal perforations and associated sepsis. All 14 mice
were from the 1% DSS-only group. Mouse weights and colon lengths
were also measured upon euthanasia and indicated colon length in
short-term treatment was decreased in the DSS group, but not in the
DSS þ American ginseng group.
Mouse colon length shrinks with stress, inﬂammation and ulcera-
tion. Therefore, as an additional indicator of inﬂammation and in-
ﬂammatory stress, mouse colon lengths were measured upon
euthanasia. For short-term (2.5 weeks) treatment, results indicate that
compared with the colon lengths of the control (water treated) group
(7.3 ± 0.2 cm), the length was signiﬁcantly reduced in the DSS group
(5.8 ± 0.6 cm). Mice consuming DSS þ American ginseng had
a non-statistically different colon length (7.1 ± 0.4 cm) to that of
the water-treated group. For long-term (14.5 weeks) treatment, results
also indicate that compared with the colon lengths of the control
(water treated) group (7.5 ± 0.9 cm), the length was signiﬁcantly re-
duced in the DSS group (4.8 ± 0.9 cm). However, in the long-term
treatment, although the level of inﬂammation and ulceration was sta-
tistically and markedly improved by American ginseng, their colon
length remained short (5.5 ± 0.5 cm). Interestingly, the ulceration/
erosion contingency Table ID for the long-term data set showed in-
sufﬁcient evidence to conclude signiﬁcant differences between the
two groups for the ulceration response. Supplementary Figure 3
(available at Carcinogenesis Online) shows representative hematox-
ylin and eosin sections from the experiment.
BecauseCD4þeffectorTcellsplayaroleindrivingcolitis(13,16,17),
we screened for inﬁltration of these cells as another end point of colitis.
Supplementary Figure 3 (available atCarcinogenesis Online) also shows
that mice consuming American ginseng have lower levels of CD4þ T
cells observed in DSS-treated mice. Iron content is doubled in the chow
of mice for this model because high iron diets are often encouraged for
UC patients, and this stimulates a Fenton reaction so that less DSS is
needed for generating colitis. We therefore examined the iron content of
tissues and conﬁrmed that all tissues had similar iron content (data not
shown), eliminating the possibility that American ginseng extract se-
questers iron as a mechanism toward tempering colitis.
To further examine the impact of American ginseng on inﬂamma-
tory markers, we examined iNOS and Cox-2. Because p53 is acti-
vated during inﬂammatory stress (6), we also probed tissue sections
for p53. Immunohistochemical staining was accomplished by rock-
ing slides using the Antibody AmpliﬁerTM to ensure even, consistent
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2353and sensitive staining. Figure 1A shows quantiﬁcation of staining,
and results indicate that all three end points of inﬂammation
(iNOS and Cox-2) and/or inﬂammatory stress (p53) are elevated in
DSS-treated mice, but reduced to normal levels when DSS-treated
mice are fed American ginseng (75 p.p.m.). Figure 1B shows repre-
sentative serial sections of iNOS, Cox-2 and p53 from all four
groups as indicated by labels.
American ginseng extract prevents oxazolone-induced colitis
DSS is directly toxic to gut epithelial cells of the basal crypts and
affects the integrity of the mucosal barrier with the subsequent in-
ﬁltration of immune (especially innate) cells (12). Intrarectal admin-
istration of the haptenating agent, oxazolone, leads to colitis with
a Th2-polarized type of response, reminiscent of human UC
(19,20). We therefore tested the hypothesis that American ginseng
can inhibit colitis in this second model. Table II shows results that
are consistent with this hypothesis. One percentage oxazolone stim-
ulates colitis. When American ginseng extract (75 p.p.m.) is given in
the diet 1 week prior toand during treatment with 1% oxazolone,mice
are signiﬁcantly protected from inﬂammation. The P-value associated
with the observed chi-square value, under the hypothesis of no differ-
ences between the two groups, is 0.0003 for the inﬂammation score.
Ulceration did not occur in this model and therefore was scored as
zero for all groups.
Mouse weights and colon lengths were also measured upon eutha-
nasia and indicated that compared with the control (water treated)
group (7.7 ± 0.7 cm), colon length was decreased in the oxaz-
olonegroup(6.8 ± 0.3cm),butnotintheoxazolone þ Americanginseng
group (8.1 ± 0.5 cm). Supplementary Figure 4 (available at Carcinogen-
esis Online) shows representative hematoxylin and eosin sections.
American ginseng extract reverses active colitis
To examine whether American ginseng extract can be used to treat
colitis, we repeated the DSS experiment with timing modiﬁcations.
Here, mice were given 1% DSS for 1.5 cycles (7 days DSS, 7 days
water and 7 days DSS) and then fed either American ginseng extract
(75 p.p.m.) or standard chow for the duration of the experiment.
Table III shows results. One percentage DSS stimulates colitis. When
American ginseng extract (75 p.p.m.) is given in the diet after 1.5
cycles, both inﬂammation and ulceration are reversed. The P-value
associated with the observed chi-squarevalue, under the hypothesis of
no differences between the two groups, is 0.0054 for the inﬂammation
score. The P-value associated with the observed chi-square value,
under the hypothesis of no differences between the two groups, is
0.0088 for the ulceration score. Supplementary Figure 5 (available
at Carcinogenesis Online) shows representative hematoxylin and
eosin sections.
American ginseng extract inhibits the activation of inﬂammatory cells
and associated DNA damage in target epithelial cells in vitro and
in vivo
Mucosal and DNA damage associated with colitis is at least in part
a result of an oxidative burst from overactive inﬂammatory cells
(17,21,22). We therefore tested the hypothesis that American ginseng
extract can inhibit leukocyte activation and resultant epithelial cell
DNA damage. In vitro, we preincubated ANA-1 mouse macrophages
with American ginseng extract (200 lg/ml, 12 h). This dose of Amer-
ican ginseng extract was chosen based on a dose response to inhibit
iNOS (supplementary Figure 1 is available at Carcinogenesis Online).
Following a 12 h incubation with American ginseng extract, cells
were washed and then IFN-c (100 U/ml media) was added to activate
Table I. Effects of American ginseng on the prevention of inﬂammation (A and B) and ulceration (C and D) in the colon induced by DSS




a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7
Water þ American ginseng 7 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7
DSS 0 (0) 0 (0) 3 (42.9) 3 (42.9) 1 (14.2) 0 (0) 7
DSS þ American ginseng
b 2 (28.6) 5 (71.4) 0 (0) 0 (0) 0 (0) 0 (0) 7
B. Long-term treatment
Water 15 (100)
a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 15
Water þ American ginseng 13 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 13
DSS 0 (0) 0 (0) 9 (30) 6 (20) 2 (6.7) 13 (43.3) 30
DSS þ American ginseng
c 1 (7.7) 0 (0) 9 (69.2) 1 (7.7) 0 (0) 2 (15.4) 13




a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7
Water þ American ginseng 7 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7
DSS 0 (0) 3 (42.9) 1 (14.2) 2 (28.7) 1 (14.2) 0 (0) 7
DSS þ American ginseng
d 6 (85.8) 1 (14.2) 0 (0) 0 (0) 0 (0) 0 (0) 7
D. Long-term treatment
Water 15 (100)
a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 15
Water þ American ginseng 13 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 13
DSS 0 (0) 7 (23.3) 7 (23.3) 2 (6.7) 1 (3.4) 13 (43.3) 30
DSS þ American ginseng
e 1 (7.7) 5 (38.5) 2 (15.4) 3 (23) 0 (0) 2 (15.4) 13
aNumber in brackets indicates percentage of mice.
bP-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups (DSS versus DSS þ American ginseng), is
0.0006.
cP-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups (DSS versus DSS þ American ginseng), is
0.0455.
dP-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups (DSS versus DSS þ American ginseng), is
0.0047.
eP-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups (DSS versus DSS þ American ginseng), is
0.2030.
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2354the macrophages. We ﬁrst screened for protection from an inﬂamma-
tory response by examining some key players in inﬂammation. We
examined iNOS and endothelial nitric oxide synthase levels, nitric
oxide release (nitrate/nitrite) and IjB phosphorylation (higher phos-
phorylation is suggestive of greater nuclear factor-kappa B (NF-jB)
activity). Figure 2A shows that IFN-c activates and American ginseng
extract reduces the activation of all markers of inﬂammation, supporting
the notion that American ginseng is an anti-inﬂammatory agent.
A consequence of the activation of macrophages is the release of
free radicals in an oxidative burst. We therefore quantiﬁed an oxida-
tive burst using chemiluminescence as described in Materials and
Methods. Figure 2B shows that American ginseng extract inhibits
an oxidative burst in cultured macrophages. Cells pretreated with
American ginseng extract for 12 h have 62% of the oxidative burst
capacity of cells not treated with American ginseng extract. This
indicates that American ginseng extract blunts a basal oxidative burst.
One hour after activation with IFN-c, cells treated with American
ginseng extract have 41% of the oxidative burst capacity of cells
not treated with American ginseng extract, indicating that American
ginseng extract also protects from an induced oxidative burst. There-
after, cells begin regaining their oxidative burst capacity, presumably
because of the depletion of American ginseng. Figure 2C highlights
the ability of American ginseng extract to inhibit oxidative stress in
ANA-1 macrophages. Green cells represent live cells releasing
reactive oxygen species. Nuclei were stained with 4#,6-diamidino-
2-phenylindole (blue).
Because an oxidative burst from macrophages can induce DNA
damage in target epithelial cells, we cocultured the macrophages
with colon cancer cells. We incubated HT29 colon cancer cells with
Fig. 1. American ginseng suppresses the players (18) involved in inﬂammation (iNOS and Cox-2) and inﬂammatory stress (p53). p53 (dilution: 1 in 1 million),
Cox-2 (dilution: 1 in 20 000) and iNOS (dilution: 1 in 10 000) were examined by immunohistochemistry, using the Antibody AmpliﬁerTM, which allows the
submersion and rocking of slides to ensure even staining and reproducible results. (A) Quantiﬁcation of iNOS, Cox-2 and p53 as indicated (mean ± SEM). All
three markers were elevated in the DSS-treated group and suppressed when the DSS-treated group were fed American ginseng (75 p.p.m.).  Indicates signiﬁcant
reduction in % positive cells in the American ginseng þ DSS group compared with the DSS group. (B) Representative serial sections of markers of inﬂammation
(iNOS and Cox-2) and inﬂammatory stress (p53) ( 400 magniﬁcation).
Table II. Effects of American ginseng on the prevention of inﬂammation in





01 2 3 4 5
Vehicle 9 (100)
a 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9
Vehicle þ American
ginseng
10 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10




0 (0) 8 (80) 2 (20) 0 (0) 0 (0) 0 (0) 10
aNumber in brackets indicates percentage of mice.
bThe P-value associated with the observed chi-square value, under the
hypothesis of no differences between the two groups, is 0.0003 for the
inﬂammation score. Ulceration did not occur in this model and therefore was
scored as zero for all groups.
American ginseng suppresses colitis
2355or without American ginseng extract dissolved in media (200 lg/
ml). We then washed the cells and added ANA-1 macrophages ac-
tivated with IFN-c as above at a 3:1 macrophage:HT29 cell ratio.
Figure 2D shows a time-dependent increase in DNA damage, as
assessed by a Comet assay. Cells preincubated with American
ginseng extract were signiﬁcantly protected from DNA damage at
4 and 8 h after the initiation of coincubation (P , 0.01). Figure 2E
shows representative Comets.
In order to test whether American ginseng extract inhibits an oxi-
dative burst and associated DNA damage in vivo, we repeated experi-
ments outlined for Table IA and C (short-term experiment) and then
separated colon epithelial mucosa from the lamina propria as de-
scribed in Materials and Methods. Figure 3A shows that DSS-treated
mice have increased levels of iNOS, endothelial nitric oxide synthase
and IjB phosphorylation (indicating NF-jB pathway activation).
These end points are attenuated in the majority of mice consuming
American ginseng extract. CD45þ cells were then examined for an
oxidative burst by chemiluminescence as described in Materials and
Methods. American ginseng extract suppresses the activity of CD45þ
inﬂammatory cells in the colon, as measured by an oxidative burst
(Figure 3B). Epithelial cells from the same mice were examined for
DNA damage by Comet analysis. Figure 3C and D shows that DNA
damage is blunted in mice consuming American ginseng extract.
Taken together, these results indicate that American ginseng extract
attenuates inﬂammatory cell activation and protects from target colon
epithelial cell damage in vivo. Such results provide mechanistic rea-
soning for the ability of American ginseng extract to attenuate muco-
sal damage associated with colitis and the possibility of protecting
from the increased risk of colon cancer.
Discussion
In recent years, there have been major advances and promising strat-
egies for the treatment of inﬂammatory bowel disease (23). Conven-
tional treatment of colitis can reduce periods of active disease and
help to maintain remission. However, most treatments often bring
side effects with marginal results and have population-speciﬁc efﬁ-
cacy. Many patients therefore turn to alternativetreatment strategies,
including Tai chi, probiotics, ﬂax seed, aloe vera and garlic (2). The
frequency of UC patients taking American ginseng is not currently
documented in the literature. Given the ability of American ginseng
to suppress key inﬂammatory players such as Cox-2, iNOS and
NF-jB (5), we hypothesized that this agent will suppress colitis.
Here, we show that American ginseng extract inhibits the onset of
colitis (Tables I and II; Figure 1; supplementary Figures 3 and 4 are
available at Carcinogenesis O n l i n e )a n dc a nb eu s e dt ot r e a tc o l i t i s
(Table III; supplementary Figure 5 is available at Carcinogenesis
Online). The doses we used of the extract were the human equivalent
of 58 mg daily. This is signiﬁcantly under that currently recommen-
ded for human consumption and doses used in clinical trials. In such
trials, 1–3g American ginseng has been shown to reduce blood sugar
levels in both healthy and diabetic people (8,9,24). Four hundred
milligrams American ginseng taken daily for 4 weeks reduced
skeletal muscle membrane damage during exhaustive exercise
(25). Although studies have shown that American ginseng does
not appear to affect blood pressure, it is of note that such studies
of long-term treatment also showed little side effects, indicating its
s a f e t yu pt o3gd a i l y( 1 0 , 2 6 ) .I ta p p e a r st h a to n eo ft h ef e ws i d e
effects are that American ginseng may reduce the effectiveness of
the anticoagulant, waraﬁn (27), and is therefore contraindicated
when taking such drugs.
We also show that American ginseng extract suppresses the activa-
tion of key inﬂammatory markers such as iNOS and Cox-2 (Figure 1).
These observations are consistent with other studies (6,28) and give
insight into the anti-inﬂammatory mechanisms invivo. Because p53 is
a marker of inﬂammatory stress, we also probed for this end point.
Our ﬁnding that p53 is also reduced indicates less inﬂammatory stress
in animals receiving American ginseng extract. Because p53 appears
to play a role in the protection from colitis by American ginseng,
future experiments will focus on the role of p53 in inﬂammatory cell
apoptosis. To this end, we have recently shown (13) that p53 over-
expression in DSS-treated mice occurs mostly in inﬂammatory cells,
providing a possible target for American ginseng as a mechanism to
protection from overactive inﬂammatory cells.
Another interesting observation, represented in Figure 1, is that
Cox-2 expression appeared in areas of high inﬂammation and ulcer-
ation near the luminal surface of the mucosa. Although iNOS and p53
expression also appeared in areas of high inﬂammation and ulcera-
tion, expression was mostly within the mucosa away from the luminal
surface. The possibility that Cox-2 expression on the borders is due to
drying effects can be ruled out because the slides were submerged in
antibody solution and rocked during incubation (see Materials and
Methods). The rationale for these expression patterns is currently
under investigation. Interestingly, the observation that p53 and iNOS
light up in similar areas is consistent with previous ﬁndings, showing
that nitric oxide drives the overexpression of p53 in colitis (6). Over-
all, there is high expression of all three end points in the DSS-treated
group, and in particular, in areas of mucosal damage.
UC and associated mucosal damage is at least partly caused by an
increased number and hyperactive inﬂammatory cells in the colon
Table III. Effects of American ginseng on treating inﬂammation and ulceration in the colon induced by DSS
Treatment group Inﬂammation score Number of mice
0 1234
DSS 1.5 cycles 0 (0)
a 0 (0) 2 (20) 2 (20) 6 (60) 10
DSS 2.5 cycles 0 (0) 0 (0) 0 (0) 5 (50) 5 (50) 10
DSS þ American ginseng 2.5 cycles 0 (0) 0 (0) 2 (28.6) 3 (42.8) 2 (28.6) 7
DSS 3.5 cycles 0 (0) 0 (0) 0 (0) 5 (35.7) 9 (64.3) 14
DSS þ American ginseng 3.5 cycles
b 0 (0) 0 (0) 5 (62.5) 3 (37.5) 0 (0) 8
Treatment group Ulceration score Number of mice
0 1234
DSS 1.5 cycles 0 (0)
a 1 (10) 6 (60) 2 (20) 1 (10) 10
DSS 2.5 cycles 0 (0) 0 (0) 4 (40) 5 (50) 1 (10) 10
DSS þ American ginseng 2.5 cycles 0 (0) 1 (14.3) 6 (85.7) 0 (0) 0 (0) 7
DSS 3.5 cycles 0 (0) 2 (14.3) 3 (21.4) 5 (35.7) 4 (28.6) 14
DSS þ American ginseng 3.5 cycles
c 0 (0) 5 (62.5) 3 (37.5) 0 (0) 0 (0) 8
aNumber in brackets indicates percentage of mice.
bThe P-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups, is 0.0054 for the inﬂammation score.
cThe P-value associated with the observed chi-square value, under the hypothesis of no differences between the two groups, is 0.0088 for the ulceration score.
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2356(17). In this study, we asked whether American ginseng extract in-
hibits the activity of inﬂammatory cells and resultant epithelial cell
DNA damage. In vitro experiments show that American ginseng ex-
tract can act on at least two levels in the colon. It can act at the level of
inﬂammatory cells by inhibiting an oxidative burst. Alternatively, in
the presence of an oxidative burst, it can directly protect epithelial
cells from DNA damage. Noteworthy, we were also able to show that
American ginseng extract reduces the activity of leukocytes and pro-
tects from damage to the colonic epithelial cell DNA in vivo. These
results are consistent with in vitro studies from other labs. For exam-
ple, red ginseng appears to protect cells from Helicobacter pylori-
driven DNA damage and cytotoxicity (29). In animals, ginseng can
inhibit micronucleus frequencies and chromosomal instability (30–
32). It can also stimulate DNA repair (32). There is a strong link
between chronic DNA damage and increased cancer risk. Based on
results presented here, we are carrying out long-term separate studies
Fig. 2. American ginseng extract attenuates the activation of macrophages and protects from DNA damage in target epithelial cells in vitro.( A) Nitrate/nitrite
production, iNOS induction, endothelial nitric oxide synthase (eNOS) phosphorylation and IjB phosphorylation (representing NF-jB activation) following
treatment of ANA-1 mouse macrophages with IFN-c.  Overall, removing the effect of time, the American ginseng extract group had signiﬁcantly lower nitrate/
nitritelevels comparedwiththeuntreated(control) group(P , 0.05,analysisofcovariance).Numbersbeloweach blotrepresentthe actin-adjusteddensityofeach
band. For endothelial nitric oxide synthase, the density of the upper (phosphorylated) band was examined because this represents an activated form of endothelial
nitric oxide synthase. The observation that, for all three markers, density is lower in unstimulated cells exposed to American ginseng extract (0 h, þGinseng, ﬁfth
lane) suggests that American ginseng extract inhibits basal activity of macrophages. Accordingly, it also inhibits the activation of macrophages. (B) An oxidative
burst in ANA-1 mouse macrophages is attenuated by pretreatment with American ginseng extract (200 lg/ml). Chemiluminescence was measured as described in
Materials and Methods. Results were compared with no ginseng control (±SEM). (C) Reactive oxygen species release, detected by ﬂuorescence as described in
Materials and Methods, is attenuated by pretreatment with American ginseng extract. Green ﬂuorescence represents oxidativelystressed cells; blue ﬂuorescence is
cell-permeant nucleic acid stain Hoechst 33342. (D) In the presence of an oxidative burst, target epithelial cells (HT29 colon cancer cells) pretreated with
American ginseng extract are protected from DNA damage. Results are represented as the mean Comet tail moment ± SEM, scoring a minimumof 50 Comets. (E)
Representative photographs of Comets.
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2357to explore the hypothesis that American ginseng extract protects mice
from inﬂammation-driven colon cancer.
In summary, we have shown American ginseng extract as a viable
treatment strategy for colitis. Our data reveal that American ginseng
directly inhibits leukocyte activation and DNA damage in target
epithelial cells of the colon. Further studies will explore whether
American ginseng extract can work upstream of the colon, in pe-
ripheral blood cells or lymphoid tissues. Indeed, other biological
therapies can cause cellular apoptosis in the spleens of treated mice
(33). A key mechanism for immune suppression is apoptosis of
overly aggressive effector T cells and defects in mucosal T cell
apoptosis is likely to play a key role in the pathogenesis of colitis
(17,22). To this end, we recognize that there are several components
of our American ginseng extract that can potentially inﬂuence the
immune system. These not only include the ginsenosides (34) but
also the polysaccharide/oligosaccharide components of the extract
mayhaveimmunomodulatoryactivity(35). Wecanruleoutaneffect
of maltodextrin since levels were almost identical between chows
with and without the addition of American ginseng extract. Al-
though, it may turn out that the most active extract is the combina-
tion of the active pharmacologic ingredients found in our American
ginseng, ultimately the question of bioactivity of the extract with
respect to colitis will be determined by bioassay-guided fraction-
ation. Currently, however, we present evidence that the use of Amer-
ican ginseng extract represents a potential therapeutic approach for
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